Efficacy of neoadjuvant chemotherapy for initially resectable colorectal liver metastases: A retrospective cohort study

Table 3 Patient characteristics after propensity score matching

Variables		Upfront hepatectomy group (n = 50)	NAC group (n = 50)	P value
Patient-related
Age (yr)	< 60	14	10	0.349
	≥ 60	36	40
Sex	Male	33	34	0.832
	Female	17	16
CEA level (ng/mL)	< 10	28	34	0.216
	≥ 10	22	16
Primary tumor-related
Site	Right	10	14	0.349
	Left	40	36
Histology	Well/moderately differentiated	49	50	0.315
	Others	1	0
Lymph node metastases	0	15	15	1.0
	≥ 1	35	35
Depth of invasion	Adjacent organ invasion (T4b)	5	3	0.461
	Others	45	47
Lymphatic invasion	0	19	23	0.418
	≥ 1	31	27
Venous invasion	0	16	15	0.829
	≥ 1	34	35
Liver metastasis-related
Number	1–3	44	42	0.564
	≥ 4	6	8
Maximum diameter (mm)	< 40	15	15	1.0
	≥ 40	35	35
Timing of the appearance	Synchronous	28	28	1.0
	Metachronous	22	22
Distribution	Unilobar	33	33	1.0
	Bilobar	17	17
Treatment-related
Staged hepatectomy	Performed	0	1	0.315
	Not performed	50	49
Surgical margins	Exposed	4	4	1.0
	Not exposed	46	46
Adjuvant chemotherapy after primary resection	Administered	17	29	0.144
	Not administered	23	21
Adjuvant chemotherapy after hepatectomy	Administered	23	17	0.221
	Not administered	27	33
Risk stratification	High-risk	18	13	0.515
	Low-risk	32	37

CEA: Carcinoembryonic antigen; NAC: Neoadjuvant chemotherapy.